A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to access a new treatment which has already shown to be effective in a small group of patients undergoing treatment of PXS-5505 in Phase 2 clinical trials. Myelofibrosis is a rare cancer of the bone marrow
Read More
How does a company with a lead asset cancer drug also get into dermatology? What does blood cancer and keloid scars have in common? The answer is: fibrosis. Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how
Read More
Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug, PXS-5505. The Company has launched new clinical trial sites in Taiwan in a planned expansion to boost patient recruitment. Designed for use in the treatment of myelofibrosis, a rare blood cancer with a poor prognosis,
Read More
In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with research into their anti-fibrotic drug pipeline. For those unfamiliar with their work, Pharmaxis is developing drugs based on their proprietary amine-oxidase technology. These drugs work by inhibiting an enzyme pathway that is key in the
Read More
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read More